9939 — Kintor Pharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$750.48m
- HK$870.57m
- CNY32.68m
Brief: Proxalutamide Phase III Clinical Trial For The Treatment Of Covid-19 Patients Approved By FDA
Brief: Kintor Pharmaceutical Says U.S. FDA Has Approved Proxalutamide's Phase Iii Covid-19 Clinical Trial
Brief: Kintor Pharmaceutical Says Investigational New Drug Application Of Gt90001's Phase Ii Clinical Trial For Advanced Hepatocellular (HCC) Approved By U.S. FDA
Brief: Kintor Pharmaceutical Says Investigational New Drug Application Of GT20029 Accepted By CDE
Brief: Kintor Pharmaceutical Says Clinical Trial Of Proxa-Rescue Androcov Trial Of Proxalutamide Approved in Brazil
Brief: Kintor Pharmaceutical Updates On Prelim Results From Clinical Trial Of Proxalutamide For Treatment Of Covid-19
Brief: Kintor's COVID-19 Trials For Proxalutamide To Expand Patient Enrolment
Brief: Kintor Pharmaceutical Gets Approval For Investigational New Drug Application Of Pyrilutamide Gel
Brief: Kintor Pharmaceutical Says Proxalutamide Clinical Trial As COVID-19 Treatment Saw First Patient Enrolment In Brazil
Brief: Kintor Pharmaceutical Says Unit Entered Exclusive License Agreement With Gensun Biopharma
HK-listed Kintor jumps on clinical trial tieup with U.S. firm for COVID-19 treatment
HK-listed drug developer Kintor rises on collaboration with JD.com
Chinese drug developer Kintor surges on Hong Kong debut